Swiss specialty pharmaceutical company Santhera Pharmaceuticals has signed an exclusive agreement with Ikris Pharma Network to distribute AGAMREE (vamorolone) in India for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older. 

The five-year agreement will see Santhera receive a percentage of net sales, in line with the terms of previous distribution agreements. Sales are expected to begin in Q4 2025 on a named patient basis.     

This latest partnership follows similar deals recently secured in Turkey and across several Gulf Cooperation Council (GCC) countries, reinforcing Santhera’s strategy to drive the global rollout of AGAMREE.

Santhera CEO Dario Eklund said, “We are pleased to partner with Ikris Pharma Network in India, which is part of our wider strategy to increase global access to AGAMREE for patients with DMD. Ikris has been actively working in the area of DMD and their expertise and dedication to ensuring rare disease drugs reach patients makes them an ideal partner in the region.”

Praveen Sikri, Founder and CEO of Ikris Pharma Network, highlighted that their collaboration with Santhera aligns with the company’s focus of addressing unmet medical needs in the rare disease community.

“We look forward to leveraging our distribution network to help DMD patients in India access this life-changing treatment,” he added.

Santhera Pharmaceuticals focuses on the development and commercialisation of innovative medicines for rare neuromuscular diseases with high unmet medical need. The company holds an exclusive worldwide license from ReveraGen for AGAMREE, a dissociative steroid with a novel mode of action, investigated in a pivotal trial as an alternative to standard corticosteroids for patients with Duchenne muscular dystrophy (DMD).

AGAMREE has been approved for the treatment of DMD by multiple regulatory authorities, including the US Food and Drug Administration (FDA), the European Commission (EC), the UK Medicines and Healthcare products Regulatory Agency (MHRA), China’s National Medical Products Administration (NMPA), and the Hong Kong Department of Health (DoH).

Ikris Pharma Network, a patient supply company, specialises in enabling access to rare disease medicines in India. The company has been actively working in the area of DMD, assisting patients and healthcare professionals in India.